Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 548

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 5
Chunk 548
---
 revenue we generate from Orpathys is primarily comprised of revenue from the sales of Orpathys to AstraZeneca as well as royalty revenue. The revenue we generate from Fruzaqla is primarily comprised of revenue from manufacturing supplies to Takeda as well as royalty revenue. Additionally, Oncology/Immunology revenue includes revenue from license and collaboration agreements for upfront, milestone and research and development services payments for our drug candidates developed in collaboration with Eli Lilly, AstraZeneca and Takeda.
The following table sets forth in-market sales by oncology products for the years indicated. For Fruzaqla, Elunate and Orpathys, they represent total sales to third parties as provided by Takeda, Eli Lilly and AstraZeneca, respectively.

        ​           ​      ​      ​    ​    ​       ​      ​    ​    ​       ​      ​    ​ 
-------------------------------------------------------------------------------------------
​                                                                   Year Ended December 31,
​                   ​                2024    ​                2023    ​                2022
​                         $’000         %          $’000         %          $’000         %
In-market sales                                                                            
Fruzaqla                290,620      58.0         15,093       7.1              —         —
Elunate                 114,992      22.9        107,518      50.3         93,462      55.9
Sulanda                  48,972       9.8         43,935      20.5         32,304      19.3
Orpathys                 45,443       9.1         46,096      21.6         41,187      24.7
Tazverik            957               0.2          1,038       0.5            128       0.1
Oncology Products       500,984     100.0        213,680     100.0        167,081     100.0
​
The following table sets forth the components of revenue of our Other Ventures by product type for the years indicated. In December 2023, we sold our interests in our consolidated joint venture Hutchison Hain Organic and our wholly own subsidiary HUTCHMED Science Nutrition, and their historical financial results and gain on divestment are reflected in our consolidated financial statements.
​